Robert Michael Dudley - 01 Feb 2022 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol: RNAZ
Transactions as of: 01 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2022, 05:03:35 UTC
Previous filing: 08 Jul 2021
Next filing: 01 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNAZ	Stock Option (Right to Buy)	Award	$0	+135,000		$0.000000	135,000	01 Feb 2022	Common Stock	135,000	$2.45	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.

Content

Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.